A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

By Lin Nancy  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1057-1065

Springer Publishing Company

Access to resources Recommend Favorite

HER2-targeted Therapeutic Strategies for HER2-positive Metastatic Breast Cancers

By  

Current Cancer Therapy Reviews, Vol. 10, Iss. 3, 2014-08 ,pp. : 225-233

Bentham Science Publishers

Access to resources Recommend Favorite

Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations

By Hagen Anne   Bofin Anna   Ytterhus Borgny   Maehle Lovise   Kjellevold Kjell   Myhre Hans   Møller Pål   Lønning Per  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 199-203

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumourrelated angiogenesis

By              

International Journal of Oncology, Vol. 45, Iss. 4, 2014-01 ,pp. : 1565-1573

Spandidos Publications

Access to resources Recommend Favorite

Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers

By Speer G.   Cseh K.   Winkler G.   Takacs I.   Nagy Z.   Lakatos P.  

European Journal of Cancer, Vol. 37, Iss. 12, 2001-08 ,pp. : 1463-1468

Elsevier

Access to resources Recommend Favorite